Related Experiment Video

Updated: Jul 20, 2026

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Oxcarbazepine therapy in very young children: a single-center clinical experience

Sanjeev V Kothare1, Navid Mostofi, Divya S Khurana

  • 1Department of Pediatrics, Division of Pediatric Neurology, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia, Pennsylvania 19134-1095, USA. Sanjeev.kothare@drexelmed.edu

Pediatric Neurology
|August 31, 2006
PubMed

Insights

Oxcarbazepine effectively reduced seizures in young children under four years old. This epilepsy medication was well-tolerated, with 70% showing seizure reduction and 50% becoming seizure-free.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology
  • Epileptology

Background:

  • Oxcarbazepine is approved for partial seizures in children aged four and older.
  • Limited data exists on oxcarbazepine's use in children under four years old.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of oxcarbazepine in pediatric patients under four years of age with epilepsy.
  • To assess oxcarbazepine's effectiveness as monotherapy and adjunctive therapy in this age group.

Main Methods:

  • Retrospective chart review of 20 pediatric patients (aged 6-45 months) treated with oxcarbazepine between 2001-2004.
  • Analysis of seizure types, treatment regimens (monotherapy vs. adjunctive), dosage, efficacy, and adverse events.

Main Results:

  • 70% of patients experienced a significant reduction in seizures.
  • 50% of patients achieved seizure freedom.
  • Transient drowsiness occurred in 20% during dose escalation; no adverse events were noted in children under two.

Conclusions:

  • Oxcarbazepine appears to be an effective and well-tolerated treatment option for partial onset seizures in pediatric patients under four years old.
  • Findings suggest potential utility of oxcarbazepine in younger children with epilepsy, warranting further investigation.

More Related Videos

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...